Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO

CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology